• Coulton Legge

    Global Open Innovation
    Bayer

19+ years in Healthcare – Pharmaceutical and Consumer (OTC / FMCG)

Physicist driven by innovation to generate commercial value (backed by intellectual property where possible), using consumer insights for new product development and investigating new technologies for unmet consumer health needs.

Current Categories of interest:
Analgesics, Allergy, Cough and Cold, Dermatology, GI, Nutritionals, Sun Care and Foot Care

Experience in building teams with multidisciplinary skills, both in UK and US and working with 3rd parties.



  • Chris Harley-Martin

    VP & Global Head, GSK Consumer Healthcare Business Development
    GSK Consumer Healthcare

Experienced Global Strategy & Corporate Development professional and adviser to early stage ventures



  • Rajesh Mishra

    Vice President R&D Consumer OTC
    Johnson & Johnson

Rajesh (Raj) Mishra M.D., PhD, currently serves as Vice President R&D Consumer OTC and Head of OTC R&D for the EMEA region based out of the UK. Raj has a wealth of U.S. and global industry experience with broad experience in OTC medicines across multiple therapeutic categories. Raj joined Johnson & Johnson Family of Consumer Companies as Vice President Medical and Clinical Affairs, Global OTC in March, 2014. In this role Raj served on the McNeil Management Board, and also on the Global OTC leadership team. Raj was responsible for providing medical and clinical oversight across the entire range of OTC therapeutic areas including pain, upper respiratory/allergy, digestive health, smoking cessation, and RX to OTC switch.

Prior to his current role at Johnson & Johnson, Raj was Vice President and Global Head Medical Affairs & Clinical Research at Merck Consumer Care. At Merck, Raj led the Global Medical and Consumer Science Innovation Center of Excellence, and had responsibility for Medical Affairs, Clinical Operations and the Consumer Science Research Center, providing strategic direction, operational, medical/clinical leadership and management for multiple franchises. Before joining Merck, Raj spent 5+ years in various roles within Medical Affairs and R&D product development at GlaxoSmithKline serving as Vice President R&D for Weight Control and Smoking Cessation and Head of Medical Affairs North America.

Raj earned his Doctor of Medicine (MD) and Masters in General Surgery (MS) at B.J. Medical College, Pune University in India. Raj also holds a Doctor of Philosophy (PhD) In Pharmacology from Southern Illinois University Carbondale School of Medicine and an Advanced Management Program Certification from Wharton, University of Pennsylvania.



  • Andrea Ponti

    Executive Partner and Founder
    GHO Capital

Andrea has 30 years of investment banking experience, focusing on healthcare since 1996. He created both JP Morgan’s and Goldman Sachs’ European investment banking healthcare franchises, advising on some of the most significant Mergers and Acquisitions for leading pharmaceutical, medical device and hospital companies but also advising emerging companies and private equity on M&A and debt or equity financing. Over the last five years he was Vice Chairman of European Investment Banking and Global co-head of Healthcare at J.P. Morgan. Prior to that Andrea was at Goldman Sachs, where he was Partner, Managing Director, Head of European Healthcare, Consumer and Retail and also Co Global Head of Healthcare and covered a variety of roles during his time at the firm including member of the firm-wide Commitments Committee. Andrea sits on the board of Cell Medica and holds a BA in Economics with Highest Honours from the University of North Carolina at Chapel Hill, where he is also a member of the Arts and Sciences Foundation Board of Directors



  • Clive Allison

    Innovation Director
    Unilever

Dr Clive Allison is Global Director of Open Innovation at Unilever one of the world’s most successful consumer goods companies. Around 200 million times a day, someone somewhere chooses a Unilever product across our Home Care, Personal Care, Foods and Refreshment product categories. At Unilever our purpose is to make sustainable living commonplace and through Open Innovation we give people and organisations the confidence to build the transformational winning partnerships required to deliver to that purpose.

Clive holds a PhD from the University of Cambridge and has more than 20 years of experience in leadership roles in R&D and Innovation across the Home and Personal Care product categories. Clive has a passion for disruptive innovation that makes a real difference in the World and in that context he leads the establishment of transformational innovation partnerships connecting Corporate, SME, Academic and Public partners to deliver business and societal impact.



  • Kevin Foley

    Vice President Worldwide Business Development
    Pfizer Consumer Healthcare



  • Siddhart Nahata

    Managing Director, Healthcare Investment Banking
    Morgan Stanley

15 years Investment Banking / 11 years at Morgan Stanley
• Joined Morgan Stanley’s Investment Banking Group in London in 2005 after spending 4 years at JPMorgan
• Worked in London, New York and Mumbai focused on biopharmaceuticals (Large Cap, Specialty and Generics) and OTC
• Graduate degree in Accounting and Finance from the University of Warwick and a post-graduate degree in Accounting and Finance from the London School of Economics

Deal Experience:
–KKRs acquisition of LGC–Sale of Roxane Laboratories to Hikma plc ($2.65Bn)
–Spin-off of Indivior from Reckitt Benckiser plc
–Sale of Omega Pharma to Perrigo (EUR 3.6Bn)
–AstraZeneca’s defence against Pfizer (~$120Bn)
–Mylan’s acquisition of Agila Specialties ($1.6Bn)–Cipla’s acquisition of Cipla Medpro South Africa ($550MM)
–Reckitt / Bristol-Myers Squibb LatAm OTC
–Pronova’s sale to BASF (NOK 5.0Bn)–Reckitt’s acquisition of Schiff Nutrition ($1.4Bn)
–AstraZeneca’s acquisition of Ardea Biosciences ($1.3Bn)
–Sale of Paras Personal Care brands by Reckitt Benckiser to Marico
–Altor’s acquisition of Orchid Orthopaedics–Sale of Paras Pharma to Reckitt Benckiser ($725MM)
–Parkway Holdings / Khazanah ($3.7Bn)
–Acquisition of Orchid Injectables by Hospira ($400MM)
-Acquisition of Piramal Healthcare by Abbott ($3.7Bn)
–Sale of Cambridge Antibody Technologies to AstraZeneca (£702MM)
–Fresenius’ acquisition of Dabur Pharma ($365MM)–Bausch & Lomb’s sale to Warburg Pincus ($4.6Bn)
–Nycomed’s acquisition of Bradley Pharmaceuticals ($346MM)
–Shire’s acquisition of New River Pharmaceuticals ($2.6Bn)
–Nycomed’s acquisition of Altana Pharma (EUR 4.2Bn)
–Sale of Cambridge Antibody Technology to AstraZeneca (GBP 702MM)
–Sale of Medi-Partenaires to Investor Group (EUR 323MM)
–IPO of Grifols, LifeCycle Pharma
–Exchangeable Bond Offering for the Govt. of Hungary
–Financings for AstraZeneca, GSK, Mylan, AstraZeneca, Shire, Nycomed, Bristol Myers and Schering-Plough



  • Barry Clare

    Partner
    Clarat Partners

Barry is a pioneering healthcare business leader with extensive experience in the healthcare industry sector. He has held a number of top roles at leading international companies and has a proven track record in developing and implementing strategy in healthcare, retail consumer products and financial services.

Barry created Boots Healthcare International, the international ‘over the counter’consumer healthcare business of the Boots Company PLC; through Barry’s leadership the business became the fastest growing ‘over the counter company’in Europe. During his time as a board member of Boots, Barry was responsible for the global expansion of international brands including Nurofen, Strepsils and Clearasil. Following his career at Boots, Barry has been Chairman of a number of successful, pioneering healthcare companies that have brought several ground breaking innovations to the NHS. Barry’s portfolio of innovative healthcare solutions include: e-health business, diagnostics tests and medicines development.